Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD

G. Ferguson (Farmington Hills, United States of America), A. Papi (Ferrara, Italy), A. Anzueto (San Antonio, United States of America), E. Kerwin (Medford, United States of America), C. Cappelletti (Durham, United States of America), E. Duncan (Durham, United States of America), J. Nyberg (Morristown, United States of America), P. Dorinsky (Durham, United States of America)

Source: International Congress 2018 – Pharmacological management of COPD
Session: Pharmacological management of COPD
Session type: Thematic Poster
Number: 775
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Ferguson (Farmington Hills, United States of America), A. Papi (Ferrara, Italy), A. Anzueto (San Antonio, United States of America), E. Kerwin (Medford, United States of America), C. Cappelletti (Durham, United States of America), E. Duncan (Durham, United States of America), J. Nyberg (Morristown, United States of America), P. Dorinsky (Durham, United States of America). Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD. 775

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: